Specialist PET/CT Imaging Requests

Item	Description
61524	BREAST CANCER Stage III, Whole body FDG PET study performed for the staging of locally advanced (Stage III) breast cancer in a patient considered potentially suitable for active therapy.
61525	BREAST CANCER Whole body FDG PET study performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma in a patient considered suitable for active therapy.
61523	SOLITARY PULMONARY NODULE evaluation, Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.
61529	NON-SMALL CELL LUNG CANCER Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.
61620	LYMPHOMA HL or NHL, Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin's or non-Hodgkin's lymphoma.
61622	LYMPHOMA HL or NHL, Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin's or non-Hodgkin's lymphoma.
61628	LYMPHOMA HL or NHL, Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin's or non-Hodgkin's lymphoma.
61632	LYMPHOMA HL or NHL, Whole body FDG PET study to assess response to second-line chemotherapy when stem cell transplantation is being considered, for Hodgkin's or non-Hodgkin's lymphoma.
61598	HEAD and NECK CANCER Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.
61604	HEAD and NECK CANCER, Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.

07 5440 9700

Please submit referrals via

07 5440 9777

info@noosaradiology.com.au

0407 822 578

*Please indicate appropriate item number & description on the referral.

noosa radiology

www.noosaradiology.com.au

Specialist PET/CT Imaging Requests

Item	Description
61610	METASTATIC SCC Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.
61541	COLORECTAL CARCINOMA Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.
61577	OESOPHAGEAL or GEJ CARCINOMA Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.
61565	OVARIAN CARCINOMA Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.
61571	UTERINE CERVIX CARCINOMA Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage 182 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.
61575	UTERINE CERVIX CARCINOMA Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.
61640	SARCOMA Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.
61646	SARCOMA Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.

07 5440 9700

Please submit referrals via

07 5440 9777

info@noosaradiology.com.au

0407 822 578

*Please indicate appropriate item number & description on the referral.

noosa radiology

www.noosaradiology.com.au

Specialist PET/CT Imaging Requests

Item	Description
61583	F-18 PSMA Initial staging Whole body prostate-specific membrane antigen PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. *Applicable once per lifetime.*
61564	F-18 PSMA restaging Whole body prostate-specific membrane antigen PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who: a) has undergone prior locoregional therapy; and b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation *Applicable twice per lifetime*
61528	PSMA LUTETIUM SUITABILITY Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
61560	ALZHEIMER'S DISEASE FDG PET study of the brain, performed for the diagnosis of Alzheimer's Disease, if: a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocat and b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and c) a service to which this item applies has not been performed on the patient in the previous 12 months; and d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's disease. *Applicable not more than 3 times per lifetime*
61538	MALIGNANT BRAIN TUMOUR FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.
61559	REFRACTORY EPILEPSY FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.

07 5440 9700

Please submit referrals via

07 5440 9777

info@noosaradiology.com.au

0407 822 578

*Please indicate appropriate item number & description on the referral.

noosa radiology

www.noosaradiology.com.au

Specialist PET/CT Imaging Requests

Item	Description
61553	MELANOMA Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.
61527	INFECTION/INFLAMMATION Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to unavailability of gallium-67
61612	RARE AND UNCOMMON CANCER Whole body FDG PET study for the initial staging of eligible cancer types, for a patient who is considered suitable for active therapy, if the eligible cancer type is: a) typically FDG avid cancer, and b) there is at least a 10% likelihood that the PET study result will inform a significant change in management for the patient. *Applicable once per cancer diagnosis* *Sample list of cancer types considered rare or uncommon:* *Anal cancer* *Bladder cancer* *Brain and other central nervous system* *Brain cancer* *Gallbladder and extrahepatic bile ducts* *Gastrointestinal stromal tumours* *Kaposi sarcoma* *Liver cancer* *Merkel cell cancer* *Mesothelioma* *Multiple myeloma* *Ovarian cancer (incidence only)* *Ovarian cancer and serious carcinomas of the fallopian tube* *Pancreatic cancer* *Penile cancer* *Peritoneal cancer* *Placenta cancer* *Small cell lung cancer* *Small intestine* *Stomach cancer* *Testicular cancer* *Thyroid cancer* *Unknown primary site* *Uterine cancer* *Vaginal cancer* *Vulvar cancer*
61614	RARE AND UNCOMMON CANCER Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer.

Should you require additional information please contact our Referrer Liaison Manager, Katrina Kellett for assistance on connect@noosaradiology.com.au or 0418 555374.

All reports and images are available via electronic download or online via Noosa Radiology Connect.

07 5440 9700

Please submit referrals via

07 5440 9777

info@noosaradiology.com.au

0407 822 578

*Please indicate appropriate item number & description on the referral.

noosa radiology

www.noosaradiology.com.au